The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
62 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $11,236,533 in first-year total cost, median $188,143.
Most frequent study sections
- Transition to Independence Study Section (I)[NCI-I (B)]18
- Transition to Independence Study Section (I)[NCI-I]15
- Special Emphasis Panel[ZCA1 RTRB-R (J1)]11
- Special Emphasis Panel[ZCA1 RTRB-R (O2)]11
- Special Emphasis Panel[ZCA1 RTRB-R (M2)]7
Most frequent institutions
- COLUMBIA UNIVERSITY HEALTH SCIENCES3
- DUKE UNIVERSITY3
- ALBERT EINSTEIN COLLEGE OF MEDICINE2
- FRED HUTCHINSON CANCER RESEARCH CENTER2
- JOHNS HOPKINS UNIVERSITY2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Targeting Oncogenic PELP1/SRC-3 Signaling Complexes in ER+ Breast Cancer1K22CA248615-01A1 | TRUONG, THU HA | UNIVERSITY OF MINNESOTA, MN | $201,744 | ZCA1 |
| 2023 | Decoding the functional pleiotropy of IL-20Rβ ligands in inflammation and tumorigenesis1K22CA266531-01 | SAXTON, ROBERT ANDREW | UNIVERSITY OF CALIFORNIA BERKELEY, CA | $200,232 | ZCA1 |
| 2023 | Understanding initiation and progression of IPMNs in pancreatic cancer1K22CA266747-01 | DESAI, RIDHDHI R | DREXEL UNIVERSITY, PA | $194,400 | ZCA1 |
| 2023 | The HDAC3 pathway in LKB1-mutant lung cancer and senescence1K22CA251636-01A1 | EICHNER, LILLIAN J. | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $191,052 | ZCA1 |
| 2023 | Targeting Adaptive Radioresistance of Glioblastoma1K22CA263305-01A1 | OSUKA, SATORU | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $108,000 | ZCA1 |
| 2022 | Potentiating the Efficacy of Immune Checkpoint Blockade by Targeting Epithelial-Mesenchymal Transition (EMT)-induced Immunosuppression in Breast Carcinomas1K22CA255420-01 | DONGRE, ANUSHKA | CORNELL UNIVERSITY, NY | $227,902 | ZCA1 |
| 2022 | Tumor-TAMs crosstalk enables bypass of oncogenic KRAS dependency in pancreatic cancer1K22CA251491-01 | HOU, PINGPING | RBHS-NEW JERSEY MEDICAL SCHOOL, NJ | $200,281 | NCI |
| 2022 | Leveraging high-risk populations for precision prevention: A novel approach for improving risk prediction for outcomes after a breast cancer diagnosis1K22CA251493-01A1 | ZEINOMAR, NUR | RUTGERS BIOMEDICAL AND HEALTH SCIENCES, NJ | $199,896 | ZCA1 |
| 2022 | Opioid-induced changes to chemotherapeutic activity in blood cancer1K22CA258671-01A1 | CONSTANCE, JONATHAN ERIC | UNIVERSITY OF UTAH, UT | $198,348 | ZCA1 |
| 2022 | Targeting Kinase Inhibitor Induced Signaling Plasticity in Patients with Ph-Like ALL1K22CA251649-01 | HURTZ, CHRISTIAN | TEMPLE UNIV OF THE COMMONWEALTH, PA | $193,104 | NCI |
| 2022 | The DF phospho-code regulating the degradation of m6A mRNA1K22CA258954-01 | ZACCARA, SARA | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $192,456 | ZCA1 |
| 2022 | The DAXX/ATRX/H3.3 axis in ERV regulation and tumor suppression1K22CA258674-01 | WASYLISHEN, AMANDA RIETTA | UNIVERSITY OF CINCINNATI, OH | $191,193 | ZCA1 |
| 2022 | Joint differentiation-state plasticity and genetic diversity modeling to predict response and improve efficacy of drug combination therapy1K22CA258799-01 | NIKOLOVA, OLGA H | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $188,485 | ZCA1 |
| 2022 | Attacking aggressive p53 mutants in gynecologic cancer1K22CA263783-01 | THIEL, KRISTINA W | UNIVERSITY OF IOWA, IA | $186,840 | ZCA1 |
| 2022 | Phase Separation-involved Roles of Mediator Complex in Myc-amplified Cancer1K22CA255404-01 | JIN, CHUNYU | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $185,760 | ZCA1 |
| 2022 | Identifying gut bacterial molecules and mechanisms that promote an anti-tumor response to immunotherapy1K22CA258960-01 | GAZZANIGA, FRANCESCA SMYLIE | HARVARD MEDICAL SCHOOL, MA | $184,656 | ZCA1 |
| 2022 | Dissecting the Functional Role of Monocytes in B-cell Acute Lymphoblastic Leukemia Survival1K22CA258520-01 | WITKOWSKI, MATTHEW | UNIVERSITY OF COLORADO DENVER, CO | $184,456 | ZCA1 |
| 2022 | Elucidating the regulation of RNA methylation by mTOR signaling in cancer1K22CA234399-01 | LEE, GINA | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $182,226 | NCI |
| 2022 | Admixture mapping of mosaic copy number alterations for identification of cancer drivers1K22CA258678-01 | JAKUBEK SWARTZLANDER, YASMINKA ALEKSANDRA | UNIVERSITY OF KENTUCKY, KY | $177,806 | ZCA1 |
| 2022 | DISSECTING THE ROLES OF FAT1 AND NEAT1 IN SOFT TISSUE SARCOMA DEVELOPMENT AND METASTASIS USING NOVEL IN VIVO SARCOMA MODELS1K22CA248849-01 | HUANG, JIANGUO | PROVIDENCE HEALTH & SERVICES - OREGON, WA | $162,000 | NCI |
| 2022 | Contribution of the Inflammasome to Radiation Response in Pancreatic Cancer1K22CA251643-01A1 | MEDLER, TERRY R | PROVIDENCE PORTLAND MEDICAL CENTER, OR | $162,000 | ZCA1 |
| 2022 | Cellular and microenvironmental mechanisms linking aging to tumor control1K22CA266150-01 | RINGEL, ALISON EPSTEIN | MASSACHUSETTS GENERAL HOSPITAL, MA | $162,000 | ZCA1 |
| 2022 | Intratumoral immunotherapy to enhance T cell infiltration and augment immune checkpoint blockade responses across molecular subtypes of breast cancer1K22CA262340-01 | CROSBY, ERIKA J | DUKE UNIVERSITY, NC | $161,486 | ZCA1 |
| 2022 | The role of SMARCAL1 in glioma telomere maintenance.1K22CA258965-01A1 | WAITKUS, MATTHEW | DUKE UNIVERSITY, NC | $152,141 | ZCA1 |
| 2022 | Identifying Novel Intensity-Specific Regulators of RAS Signaling1K22CA266753-01 | KABIRI, ZAHRA | DUKE UNIVERSITY, NC | $133,907 | ZCA1 |
| 2021 | Investigating the biology and therapeutic vulnerabilities of ER+ metastatic breast cancer with activating HER2 mutations1K22CA241377-01A1 | NAYAR, UTTHARA | JOHNS HOPKINS UNIVERSITY, MD | $195,220 | NCI |
| 2021 | Investigation of the mitochondrial function in GNAS mutant neoplasms1K22CA237817-01 | PATRA, KRUSHNA CHANDRA | UNIVERSITY OF CINCINNATI, OH | $195,196 | NCI |
| 2021 | Tumor-directed immunostimulatory nanoparticles for novel 'prime-pull'cancer vaccination1K22CA262355-01 | ATUKORALE, PRABHANI | UNIVERSITY OF MASSACHUSETTS AMHERST, MA | $194,524 | ZCA1 |
| 2021 | Glycosylation as a Regulator of Tropism of Melanoma Metastasis - Resubmission - 11K22CA229600-01A1 | AGRAWAL, PRAVEEN | ALBERT EINSTEIN COLLEGE OF MEDICINE, NY | $194,400 | NCI |
| 2021 | Investigating the role of RUNX2 activation across cancer evolution in lung adenocarcinoma1K22CA258957-01 | LAFAVE, LINDSAY MARIE | ALBERT EINSTEIN COLLEGE OF MEDICINE, NY | $194,400 | ZCA1 |
| 2021 | The immunosuppressive function of secretory IgM in tumor-bearing mice1K22CA248354-01 | TANG, CHIH-HANG ANTHONY | METHODIST HOSPITAL RESEARCH INSTITUTE, TX | $194,184 | NCI |
| 2021 | Anti-cancer therapeutic approaches for targeting the ALT telomere maintenance mechanism1K22CA245259-01A1 | MIN, JAEWON | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $192,456 | NCI |
| 2021 | Novel Molecular Functions of WEE1 in Esophageal Adenocarcinoma1K22CA255424-01 | CHEN, ZHENG | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $191,592 | ZCA1 |
| 2021 | Targeting abnormal immunomechanics in the glioblastoma microenvironment to improve therapeutic response1K22CA258410-01 | DATTA, MEENAL | UNIVERSITY OF NOTRE DAME, IN | $191,052 | ZCA1 |
| 2021 | Mechanisms of epigenetic regulation of estrogen receptor function in breast cancer1K22CA245487-01A1 | TOSKA, ENEDA | JOHNS HOPKINS UNIVERSITY, MD | $187,800 | NCI |
| 2021 | Mechanisms Of Akt Regulation1K22CA241105-01A1 | CHU, NAM KY | OHIO STATE UNIVERSITY, OH | $187,272 | NCI |
| 2021 | Characterizing an alternatively spliced NTRK2 isoform in development and cancer1K22CA258953-01 | PATTWELL, SIOBHAN | SEATTLE CHILDREN'S HOSPITAL, WA | $187,056 | ZCA1 |
| 2021 | Chemical Epigenomic Strategies to Overcome Metastatic Castration Resistant Prostate Cancer1K22CA255594-01 | GRYDER, BERKLEY E | CASE WESTERN RESERVE UNIVERSITY, OH | $175,095 | ZCA1 |
| 2021 | Unraveling the MALAT1 lncRNA-protein interaction networks that drive lung cancer metastasis1K22CA262349-01 | WEIDMANN, CHASE A | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $162,000 | ZCA1 |
| 2021 | A transcription-independent role of HSF1 in tumorigenesis via suppression of AMPK1K22CA248616-01 | SU, KUO-HUI | UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS, OH | $161,962 | NCI |
| 2021 | HPV alternative splicing in cervical cancer radiation response1K22CA237839-01A1 | ZHANG, JIN | WASHINGTON UNIVERSITY, MO | $155,516 | NCI |
| 2021 | Targeted disruption of the YAP/TAZ/TEAD axis in pancreatic cancer1K22CA258805-01 | NABET, BEHNAM | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $110,651 | ZCA1 |
| 2020 | A Molecular Study of Rag GTPase-Dependent Amino Acid Sensing1K22CA241362-01 | SHEN, KUANG | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $204,163 | NCI |
| 2020 | Pathological epigenetic hyper-plasticity promotes acquisition of pro-tumor states in cancer1K22CA237846-01A1 | FLAVAHAN, WILLIAM ALEXANDER | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $200,409 | NCI |
| 2020 | Functional Approaches to Understanding Cancer Aneuploidy: Interrogating the Effects of Chromosome 3p Deletion1K22CA237733-01 | TAYLOR, ALISON M. | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $192,456 | NCI |
| 2020 | Enhanced Immunotherapy by Targeting the Pros1:Macrophage Mer Axis1K22CA237742-01 | UBIL, ERIC S | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $192,352 | NCI |
| 2020 | Identifying driver non-coding alterations in metastatic prostate cancer from tumor and cell-free DNA1K22CA237746-01 | HA, GAVIN | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $189,432 | NCI |
| 2020 | Oncogenic Roles and Therapeutic Potential of MCL1 Addiction in Primary Effusion Lymphoma1K22CA241355-01A1 | MANZANO, MARK | UNIV OF ARKANSAS FOR MED SCIS, AR | $183,707 | NCI |
| 2020 | Targeting ANGPTL4 in obesity-driven breast cancer progression1K22CA229595-01A1 | KOLB, RYAN H | UNIVERSITY OF FLORIDA, FL | $179,714 | NCI |
| 2020 | Metabolic and epigenetic drivers of stem cells in obesity and cancer1K22CA241083-01 | MANA, MIYEKO | ARIZONA STATE UNIVERSITY-TEMPE CAMPUS, AZ | $177,149 | NCI |
| 2020 | The role of PP2A B56a in pancreatic tumorigenesis1K22CA237620-01A1 | ALLEN-PETERSEN, BRITTANY | PURDUE UNIVERSITY, IN | $174,844 | NCI |
| 2020 | TET-mediated Epigenetic Regulation in the Development and Immunoevasion of B cell Lymphoma1K22CA241290-01 | LIO, JERRY CHAN-WANG | OHIO STATE UNIVERSITY, OH | $161,751 | NCI |
| 2020 | Myeloid Syk promotes tumor immunosuppression and inhibits anti-tumor adaptive immunity1K22CA229594-01A1 | JOSHI, SHWETA | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $161,230 | NCI |
| 2020 | Characterizing and targeting intra-tumor heterogeneity in triple negative breast cancer chemoresistance and multi-organ metastasis1K22CA241113-01 | ECHEVERRIA, GLORIA VITTONE | BAYLOR COLLEGE OF MEDICINE, TX | $157,680 | NCI |
| 2020 | ROLE OF MIDKINE IN MOLECULAR TARGETED THERAPY TO TIP1 FOR LUNG CANCER TREATMENT1K22CA234404-01A1 | KAPOOR, VAISHALI | WASHINGTON UNIVERSITY, MO | $153,211 | NCI |
| 2019 | Improving shared decision making in cancer screening1K22CA234400-01A1 | CARLSSON, SIGRID | SLOAN-KETTERING INST CAN RESEARCH, NY | $198,064 | NCI |
| 2019 | Targeting altered nitrogen metabolism in an aggressive subset of human lung cance1K22CA226676-01A1 | KIM, JIYEON | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $197,082 | NCI |
| 2019 | Overcoming barriers to cancer screening among women living in rural and segregated communities1K22CA225705-01A1 | MOSS, JENNIFER LINDSAY | PENNSYLVANIA STATE UNIV HERSHEY MED CTR, PA | $194,944 | NCI |
| 2019 | High-Throughput Functional Genomics to Guide Precision Oncology in Gastrointestinal Tumors1K22CA234406-01 | SHEN, JOHN PAUL YING CHING | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $192,240 | NCI |
| 2019 | Use of Physiologic Media to Study Metabolic Regulation and Requirements in Cancer1K22CA225864-01A1 | CANTOR, JASON ROBERT | MORGRIDGE INSTITUTE FOR RESEARCH, INC., WI | $189,797 | NCI |
| 2019 | Novel Approaches to Modeling and Treating IDH1 Mutant Glioma1K22CA237752-01 | MCBRAYER, SAMUEL KENT | UT SOUTHWESTERN MEDICAL CENTER, TX | $177,473 | NCI |
| 2019 | Nuclear body assembly and function in telomerase-free cancer cells1K22CA237632-01 | ZHANG, HUAIYING | CARNEGIE-MELLON UNIVERSITY, PA | $166,088 | NCI |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.